Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.14348/molcells.2021.0026 http://scihub22266oqcxt.onion/10.14348/molcells.2021.0026 34059561!8245319!34059561     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mol+Cells 2021 ; 44 (6): 408-421 Nephropedia Template TP {{tp|p=34059561|t=2021. Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions |pdf=|usr=}}{{34059561}} gab.com Text Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions JO: Mol Cells http://www.kidney.de/pget.php?&tw=1&pmid=34059561 #FOAvip The outbreak of coronavirus disease 2019 (COVID-19) has not only affected human health but also diverted the focus of research and derailed the world economy over the past year. Recently, vaccination against COVID-19 has begun, but further studies on effective therapeutic agents are still needed. The severity of COVID-19 is attributable to several factors such as the dysfunctional host immune response manifested by uncontrolled viral replication, type I interferon suppression, and release of impaired cytokines by the infected resident and recruited cells. Due to the evolving pathophysiology and direct involvement of the host immune system in COVID-19, the use of immune-modulating drugs is still challenging. For the use of immune-modulating drugs in severe COVID-19, it is important to balance the fight between the aggravated immune system and suppression of immune defense against the virus that causes secondary infection. In addition, the interplaying events that occur during virus-host interactions, such as activation of the host immune system, immune evasion mechanism of the virus, and manifestation of different stages of COVID-19, are disjunctive and require thorough streamlining. This review provides an update on the immunotherapeutic interventions implemented to combat COVID-19 along with the understanding of molecular aspects of the immune evasion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which may provide opportunities to develop more effective and promising therapeutics. Twit Text FOAVip Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions ????Mol Cells http://www.kidney.de/pget.php?&tw=1&pmid=34059561 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34059561 #FOAvip English Wikipedia <ref>{{Cite pmid|34059561}}</ref> Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions #MMPMID34059561 Shah M; Woo HG Mol Cells 2021[Jun]; 44 (6): 408-421 PMID34059561show ga The outbreak of coronavirus disease 2019 (COVID-19) has not only affected human health but also diverted the focus of research and derailed the world economy over the past year. Recently, vaccination against COVID-19 has begun, but further studies on effective therapeutic agents are still needed. The severity of COVID-19 is attributable to several factors such as the dysfunctional host immune response manifested by uncontrolled viral replication, type I interferon suppression, and release of impaired cytokines by the infected resident and recruited cells. Due to the evolving pathophysiology and direct involvement of the host immune system in COVID-19, the use of immune-modulating drugs is still challenging. For the use of immune-modulating drugs in severe COVID-19, it is important to balance the fight between the aggravated immune system and suppression of immune defense against the virus that causes secondary infection. In addition, the interplaying events that occur during virus-host interactions, such as activation of the host immune system, immune evasion mechanism of the virus, and manifestation of different stages of COVID-19, are disjunctive and require thorough streamlining. This review provides an update on the immunotherapeutic interventions implemented to combat COVID-19 along with the understanding of molecular aspects of the immune evasion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which may provide opportunities to develop more effective and promising therapeutics. |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19 Serotherapy[MESH] |COVID-19 Vaccines/administration & dosage[MESH] |COVID-19/immunology/pathology/prevention & control/*therapy[MESH] |Clinical Trials as Topic[MESH] |Cytokines/antagonists & inhibitors/biosynthesis[MESH] |Dexamethasone/therapeutic use[MESH] |Drug Combinations[MESH] |Humans[MESH] |Immune Evasion/*drug effects[MESH] |Immunity, Innate/drug effects[MESH] |Immunization, Passive/methods[MESH] |Immunologic Factors/*therapeutic use[MESH] |Interleukin 1 Receptor Antagonist Protein/therapeutic use[MESH] |Peptides/therapeutic use[MESH] |SARS-CoV-2/drug effects/immunology/pathogenicity[MESH]Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and T(epmc).pdf DeepDyve Pubget Overpricing